Clinical Trial Update: Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid

View source ↗

Summary

Completed clinical trial assessing the effect of Aricept on cerebrospinal fluid biomarkers (acetylcholine and sAPP alpha) in Alzheimer's disease and dementia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• Aricept (Donepezil)

Snippet

Sponsor: Pfizer | Conditions: Alzheimer's Disease, Dementia | Status: COMPLETED